

Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)  
CIN: U36994KA2017PLC105721

Annexure I - Restated Statement of Assets and Liabilities

(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

Particulars	Note	As at		As at	
		31 December 2023	31 March 2023	31 March 2022	31 March 2021
<b>EQUITY AND LIABILITIES</b>					
<b>Shareholder's funds</b>					
Share capital	3	5.00	3.00	3.00	3.00
Reserves and surplus	4	1,557.63	457.23	145.79	(111.58)
<b>Sub-total (A)</b>		<b>1,562.63</b>	<b>460.23</b>	<b>148.79</b>	<b>(108.58)</b>
<b>Non-current liabilities</b>					
Long-term provisions	5	29.38	26.85	14.50	8.51
<b>Sub-total (B)</b>		<b>29.38</b>	<b>26.85</b>	<b>14.50</b>	<b>8.51</b>
<b>Current liabilities</b>					
Short term borrowings	6	-	3.50	12.11	12.11
Trade payables	7	-	-	-	-
- due to micro and small enterprises		107.74	303.51	11.01	141.90
- due to other than micro and small enterprises		11.46	214.89	232.19	365.02
Other current liabilities	8	174.49	230.39	240.12	410.02
Short-term provisions	9	128.64	0.06	0.03	0.01
<b>Sub-total (C)</b>		<b>422.33</b>	<b>752.35</b>	<b>495.46</b>	<b>929.06</b>
<b>Total (A+B+C)</b>		<b>2,014.34</b>	<b>1,239.43</b>	<b>658.75</b>	<b>828.99</b>
<b>ASSETS</b>					
<b>Non-current assets</b>					
<b>Property, plant and equipment</b>					
- Tangible assets	10	60.94	48.95	38.67	71.74
- Intangible assets	11	2.58	3.10	5.63	8.02
- Capital work in progress	12	21.25	-	-	-
- Intangible assets under development	13	17.65	-	-	-
Deferred tax asset (net)	14	8.91	10.42	6.22	3.33
Long term loans and advances	15	4.99	4.99	4.36	2.66
Other non-current assets	16	-	33.58	44.02	20.48
<b>Sub-total (A)</b>		<b>116.32</b>	<b>101.04</b>	<b>98.90</b>	<b>106.23</b>
<b>Current assets</b>					
Inventories	17	104.63	317.96	205.76	249.50
Trade receivables	18	803.23	123.20	87.53	441.37
Cash and cash equivalents	19	745.70	584.04	240.80	4.88
Other bank balances	19	102.85	101.32	-	-
Short-term loans and advances	20	126.52	5.52	25.73	10.61
Other current assets	21	15.09	6.35	0.03	16.40
<b>Sub-total (B)</b>		<b>1,898.02</b>	<b>1,138.39</b>	<b>559.85</b>	<b>722.76</b>
<b>Total (A+B)</b>		<b>2,014.34</b>	<b>1,239.43</b>	<b>658.75</b>	<b>828.99</b>
Significant accounting policies	1 & 2				
Notes to financial statements	3 to 43				

The above Annexure should be read with the Basis of Preparation and Significant Accounting Policies appearing in Annexure IV, Notes to the Restated Financial Statements and Statement of Adjustments to the Restated Financial Statements appearing in Annexure V.

As per our report of even date

For SKLR & Co. LLP  
Chartered Accountants  
Firm Registration No. W100362

*Lallesh Gade*  
Partner  
Membership No.: 155999  
UDIN No.: 24155999BKAJAO3399  
Place: Bangalore  
Date: 13-04-2024



For and on behalf of the Board of Directors of  
Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)

*Tarun Gandhi*  
Managing Director  
DIN: 07854699  
*Sharanya X*  
Sharanya Nagaraj  
Chief financial officer

Place: Bangalore  
Date: 13-04-2024

*Anand Gandhi*  
Managing Director  
DIN: 07854706

*Sapna Parmar*  
Company Secretary



**Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)**

CIN: U36994KA2017PLC105721

**Annexure II - Restated Statement of Profit and Loss**

(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

Particulars	Note	For the period ended 31 December 2023	Year ended 31 March 2023	Year ended 31 March 2022	Year ended 31 March 2021
<b>Income</b>					
Revenue from operations	22	3,578.83	3,016.63	2,761.32	1,799.94
Other income	23	26.36	11.62	0.22	-
<b>Total income</b>		<b>3,605.19</b>	<b>3,028.25</b>	<b>2,761.54</b>	<b>1,799.94</b>
<b>Expenses</b>					
Materials produced	24	754.30	1,019.04	833.33	1,052.47
Changes in inventories of materials in hand	25	213.33	(112.20)	43.74	(249.50)
Employee benefit expenses	26	420.29	747.81	639.17	385.19
Finance cost	27	4.38	-	-	-
Depreciation and amortization expense	28	16.06	23.75	32.75	0.65
Other expenses	29	719.67	932.41	879.08	714.25
<b>Total expenses</b>		<b>2,128.03</b>	<b>2,610.81</b>	<b>2,428.07</b>	<b>1,903.07</b>
<b>Restated profit/(loss) before tax</b>		<b>1,477.16</b>	<b>417.44</b>	<b>333.47</b>	<b>(103.13)</b>
<b>Tax expense</b>					
Current tax	9	375.24	110.20	79.00	-
Deferred tax - charge/ (credit)	14	1.52	(4.20)	(2.90)	(3.33)
<b>Restated profit/(loss) after tax</b>		<b>1,100.40</b>	<b>311.44</b>	<b>257.37</b>	<b>(99.80)</b>
<b>Basic and diluted earnings per share</b>	32	7.05	2.00	1.65	(0.64)
Equity shares [Face value of Rs. 10 each]					
<b>Significant accounting policies</b>	1 & 2				
<b>Notes to financial statements</b>	3 to 43				


The above Annexure should be read with the Basis of Preparation and Significant Accounting Policies appearing in Annexure IV, Notes to the Restated Financial Statements and Statement of Adjustments to the Restated Financial Statements appearing in Annexure V.

As per our report of even date

**For SKLR & Co. LLP**

Chartered Accountants

Firm Registration No.: W100362


**Latesh Gada**

Partner

Membership No.: 155999

UDIN No.: 24155999BKAJAG8306

Place: Bangalore

Date: 13-04-2024

**For and on behalf of the Board of Directors of****Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)**

**Tarun Gandhi**  
 Managing Director  
 DIN: 07854699


**Sharanya Nagaraj**  
 Chief financial officer

Place: Bangalore

Date: 13-04-2024


**Anand Gandhi**  
 Managing Director  
 DIN: 07854706


**Sapna Parmar**  
 Company Secretary


Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)  
CIN: U36994KA2017PLC105721  
Annexure III - Restated Cash Flow Statement  
(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

Particulars	Note	For the period ended 31 December 2023	Year ended 31 March 2023	Year ended 31 March 2022	Year ended 31 March 2021
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>					
Restated profit/(loss) before tax		1,477.16	417.44	333.47	(103.13)
Adjustments for :					
Depreciation and amortisation expense		16.06	23.75	32.75	0.65
(Profit)/Loss on sale of property, plant and equipment		(2.78)	-	8.77	-
Interest income on bank deposits		(23.24)	(9.98)	(0.22)	-
Interest income on income tax refund		(0.34)	(1.64)	-	-
<b>Operating profit/ (loss) before changes in assets and liabilities</b>		<b>1,466.86</b>	<b>429.57</b>	<b>374.77</b>	<b>(102.48)</b>
Movements in working capital : [Including Current and Non-current]					
(Increase)/decrease in Trade receivables		(680.03)	(35.68)	353.84	(441.38)
(Increase)/decrease in Inventories		213.33	(112.20)	43.74	(249.50)
(Increase)/decrease in Loans and advances		(121.01)	19.59	(16.82)	(11.14)
(Increase)/decrease in Other assets		(12.36)	(0.16)	16.37	(16.38)
Increase/(decrease) in Trade payables		(399.19)	275.20	(263.73)	497.14
Increase/(decrease) in Other liabilities		(55.85)	(9.77)	(109.84)	342.77
Increase/(decrease) in Provisions		4.78	12.39	6.01	8.52
<b>Adjustments for :</b>		<b>416.53</b>	<b>578.95</b>	<b>404.35</b>	<b>27.57</b>
Direct taxes paid [Including tax deducted at source] - (net)		(215.01)	(99.76)	(102.54)	(20.48)
<b>Net cash provided by operating activities (A)</b>		<b>201.52</b>	<b>479.19</b>	<b>301.81</b>	<b>7.09</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>					
Purchase of property, plant and equipment and capital expenditure made		(69.15)	(31.47)	(11.07)	(80.32)
Proceeds from sale of property, plant and equipment		5.47	-	5.00	-
Interest received		26.85	5.44	0.22	-
Proceeds from maturity of fixed deposits/ (investment) during the year (Net)		(1.53)	(101.32)	-	-
<b>Net cash used in investing activities (B)</b>		<b>(38.36)</b>	<b>(127.35)</b>	<b>(5.85)</b>	<b>(80.32)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>					
Proceeds from issue of share capital		2.00	-	-	-
Proceeds from short term borrowings		-	2.52	0.66	8.06
Repayment of short term borrowings		(3.50)	(11.12)	(0.66)	(0.45)
<b>Net cash used in financing activities (C)</b>		<b>(1.50)</b>	<b>(8.60)</b>	<b>-</b>	<b>7.61</b>
<b>Net Increase / (decrease) in cash and cash equivalents (A+B+C)</b>		<b>161.66</b>	<b>343.24</b>	<b>295.96</b>	<b>(65.62)</b>
Cash and cash equivalents at beginning of the period/ year		584.04	240.80	(55.16)	10.46
Cash and cash equivalents at end of the period/year	19	745.70	584.04	240.80	(55.16)
<b>Net Increase / (decrease) in cash and cash equivalents</b>		<b>161.66</b>	<b>343.24</b>	<b>295.96</b>	<b>(65.62)</b>

Notes :

- Cash flow statement has been prepared as per "indirect method" as set out in AS 3 - "Cash Flow Statement"
- Breakup of cash and cash equivalent is as given below.



Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)  
CIN: U36994KA2017PLC105721

**Annexure III - Restated Cash Flow Statement**

(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

Particulars	Note	As at			
		31 December 2023	31 March 2023	31 March 2022	31 March 2021
<b>Cash and Cash Equivalents</b>					
- Cash in Hand		8.92	8.65	7.53	4.88
- Balance with bank in current accounts		444.93	2.09	233.27	-
Fixed deposits with bank- Sweep-in facility		291.85	573.30	-	-
Less - Bank balance, book overdrawn	8	-	-	-	(60.04)
<b>Net cash and cash equivalents</b>	19	<b>745.70</b>	<b>584.04</b>	<b>240.80</b>	<b>(55.16)</b>

Significant accounting policies 1 & 2  
Notes to financial statements 3 to 43

The above Annexure should be read with the Basis of Preparation and Significant Accounting Policies appearing in Annexure IV, Notes to the Restated Financial Statements and Statement of Adjustments to the Restated Financial Statements appearing in Annexure V.

As per our report of even date

For SKLR & Co. LLP  
Chartered Accountants  
Firm Registration No. W100362

*Latesh Gada*  
Latesh Gada  
Partner  
Membership No.: 155999  
UDIN No.: 24155999BKAJAC6306

Place: Bangalore  
Date: 13-04-2024



For and on behalf of the Board of Directors of  
Amwill Health Care Limited (Formerly Known As Amwill Health Care Private Limited)

*Tarun Gandhi*  
Tarun Gandhi  
Managing Director  
DIN: 07854699

*Sharanya N*  
Sharanya Nagaraj  
Chief financial officer

Place: Bangalore  
Date: 13-04-2024

*Anand Gandhi*  
Anand Gandhi  
Managing Director  
DIN: 07854708

*Sapna Parmar*  
Sapna Parmar  
Company Secretary





per share amounts, unless otherwise stated. Wherever an amount is represented as INR '0.00' (zero) it construes a value less than rupees five hundred.

### **2.3 Use of estimates**

The preparation of the Restated Financial Statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the application of accounting policies, reported balances of assets and liabilities, disclosure of contingent liabilities as on the date of Restated Financial Statements and reported amounts of income and expenses during the period. Management believes that the estimates and assumptions used in the preparation of Restated Financial Statements are prudent and reasonable. Actual results could differ from those estimates. Any difference between the actual results and estimates are recognised in the period in which the results are known / materialise. Any revision to accounting estimates is recognized prospectively in the current and future periods.

### **2.4 Investments**

Investments are classified into current and long - term investments.

Investments that are readily realizable and intended to be held for not more than a year from the date on which such investments are made are classified as current investments. All other investments are classified as non-current investments.

Current investments are carried at lower of cost and fair value determined on an individual investment basis. Non-current investments are carried at cost. However, provision for diminution in value of long-term investments is made to recognise a decline, other than temporary, on an individual investment basis.

Long term investments which are expected to be realized within twelve months from the balances sheet date are presented under 'current investments' as 'current portion of loan term investments' in accordance with the current / noncurrent classification of investments as per Schedule III of the Companies Act, 2013.

The cost of investments comprises purchase price and directly attributable acquisition charges such as brokerage, fees and duties.

Investment transactions are accounted for on a trade date basis. In determining the holding cost of investments and the gain or loss on sale of investments, the 'weighted average cost' method is followed

On disposal of an investment, the difference between its carrying amount and net disposal proceeds is charged or credited to the Statement of Profit and Loss.

### **2.5 Revenue Recognition**

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured.



**Annexure IV- Significant Accounting Policies to Restated Financial Statements**

Interest income is recognised on time proportion basis taking into account the amount outstanding and rate applicable.

Dividend income on investment is accounted for in the period/year in which the right to receive the payment is established.

**2.6 Borrowing cost**

Borrowing costs that are directly attributable to the acquisition, construction or development of a qualifying asset are capitalized as part of the cost of the respective asset till such time the asset is ready for its intended use or sale. A qualifying asset is an asset which necessarily takes substantial period of time to get ready for its intended use or sale. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest, exchange difference arising from foreign currency borrowings to the extent they are treated as an adjustment to the borrowing cost and other costs that an entity incurs in connection with the borrowing of funds.

**2.7 Taxes on income**

Tax expenses comprises of current tax, deferred tax charge or credit and adjustments of taxes for earlier years.

Provision for current tax is made as per the provisions of Income Tax Act, 1961.

Deferred tax charge or credit reflects the impact of current period timing differences between taxable income and accounting income for the period and reversal of timing differences of earlier years and are measured based on the tax rates and the tax laws enacted or substantively enacted at the balance sheet date.

Deferred tax assets are recognised only to the extent there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised. In situations where the Company has unabsorbed depreciation or carry forward tax losses, all deferred tax assets are recognised only if there is virtual certainty supported by convincing evidence that they can be realised against future taxable profits. Deferred tax assets are reviewed for the appropriateness of their respective carrying amounts at each balance sheet date.

**2.8 Cash and cash equivalents**

Cash and cash equivalents include cash in hand, bank balances, deposits with bank (other than on lien) and all short term and highly liquid investments that are readily convertible into known amounts of cash and are subject to an insignificant risk of change in value.

**2.9 Cash flow statement**

Cash flows are reported using the indirect method, whereby net profit/loss before tax is adjusted for the effects of transactions of non-cash nature, any deferrals of accruals of past or future operating cash receipts or payments and item of income or expense associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.



## 2.10 Inventories

Inventories are valued at lower of cost or net realisable value. Cost is determined on a First In-First Out (FIFO) basis and includes all applicable costs, including inward freight, incurred in bringing goods to their present location and condition.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale. Provisions are made towards slow-moving and obsolete items based on historical experience of utilisation on a product category basis, which consideration of product lines and market conditions.

## 2.11 Foreign currency transactions

Transactions in foreign currency are recorded at exchange rates prevailing at the date of transactions. Exchange differences arising on foreign exchange transactions settled during the period/year are recognised in the statement of profit and loss of the period/year.

Monetary assets and liabilities denominated in foreign currencies which are outstanding, as at the reporting period are translated at the closing exchange rates and the resultant exchange differences are recognised in the statement of profit and loss.

Non-monetary assets and liabilities denominated in foreign currencies that are measured in terms of historical cost are translated using the exchange rate at the date of the transaction.

Non-monetary items, which are measured at fair value or other similar valuation denominated in a foreign currency, are translated using the exchange rate at the date when such value was determined.

## 2.12 Employee benefits

- **Short-term employee benefits**

Employee benefits payable wholly within twelve months of rendering the service are classified as short-term employee benefits. The undiscounted amount of short-term employee benefits expected to be paid in exchange for the services rendered by employees is recognized during the period/year.

- **Post-employment benefits**

- (a) **Defined contribution plans**

Contributions to the provident fund, which is defined contribution scheme, are recognised as an employee benefit expense in the statement of profit and loss in the period in which the contribution is due. Contributions are made in accordance with the rules of the statute and are recognised as expenses when employees render service entitling them to the contributions.

- (b) **Defined benefit plans**





**Annexure IV- Significant Accounting Policies to Restated Financial Statements**

The employees' gratuity scheme is a defined benefit plan. The present value of the obligation under such defined benefit plans is determined based on actuarial valuation using the projected unit credit method, which recognises each period of service as giving rise to additional unit of employee benefit entitlement and measures each unit separately to build up the final obligation.

The obligation is measured at the present value of the estimated future cash flows. The discount rates used for determining the present value of the obligation under defined benefit plans, is based on the market yields on government securities as at the reporting date, having maturity periods approximating to the terms of related obligations.

In case of funded plans, the fair value of the planned assets is reduced from the gross obligation under the defined benefit plans, to recognise the obligation on net basis.

When the benefits of the plan are changed or when a plan is curtailed, the resulting change in benefits that relates to past service or the gain or loss on curtailment is recognised immediately in the statement of profit and loss. Net interest is calculated by applying the discount rate to the net defined benefit liability or asset. The Company recognises gains/ losses on settlement of a defined plan when the settlement occurs.

**2.13 Property, plant and equipment**

• **Recognition and measurement**

Property, plant and equipment are stated at cost, net of accumulated depreciation (other than freehold land) and impairment losses, if any. The cost comprises purchase price, borrowing costs if capitalisation criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. Capitalisation of costs in the carrying amount of property, plant and equipment ceases when the item is in the location and condition necessary for it to be capable of operating in the manner intended by the Company. Any trade discounts and rebates are deducted in arriving at the purchase price.

The Company identifies and determines cost of each component/ part of the asset separately, if the component/ part has a cost which is significant to the total cost of the asset and has useful life that is materially different from that of the remaining asset. These components are depreciated separately over their useful lives; the remaining components are depreciated over the life of the principal asset.

• **Subsequent costs**

Subsequent expenditure related to an item of property, plant and equipment is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance. Incomes and expenses related to the incidental operations not necessary to bring the item to the location and the condition necessary for it to be capable of operating in the manner intended by the Company are recognised in the Statement of profit and loss. All other expenses on existing property, plant and equipment, including day-to-day repair and maintenance expenditure and cost of replacing parts, are charged to the Statement of Profit & Loss for the period/year in which such expenses are incurred.

Capital work-in-progress comprises of property, plant and equipment that are not ready for their intended use at the end of reporting period and are carried at cost comprising direct costs, related incidental expenses, other directly attributable costs and borrowing costs.

• **Disposal**



**Annexure IV- Significant Accounting Policies to Restated Financial Statements**

An item of property, plant and equipment is derecognised upon disposal or when no future benefits are expected from its use or disposal. Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment, and are recognised net within other income/ expenses in the statement of profit and loss.

• **Depreciation**

Depreciation on Property, plant and equipment's is calculated on pro rata basis on straight-line method using the management assessed useful lives of the assets which is in line with the manner prescribed in Schedule II of the Companies Act, 2013. The useful life is as follows:

Class of asset	Useful lives as per schedule II (Years)	Useful lives considered as per management estimate (Years)
Plant and equipments	15	5
Furniture and fixtures	10	10
Office equipments	5	5
Computers	3	3
Vehicles	8 to 10	8 – 10
Electrical Installations and Equipments	5	5

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at regular intervals and adjusted prospectively, if appropriate.

Leasehold improvements are depreciated over the primary lease period.

**2.14 Intangible Assets**

• **Recognition and measurement**

Intangible assets are recognised when the asset is identifiable, is within the control of the Company, it is probable that the future economic benefits that are attributable to the asset will flow to the Company and cost of the asset can be reliably measured.

Intangible assets acquired separately are measured on initial recognition at cost. Intangible assets acquired by the Company that have finite useful lives are measured at cost less accumulated amortisation and any accumulated impairment losses. Intangible assets with indefinite useful lives are not amortised, but are tested for impairment annually, either individually or at the cash-generating unit level.

Expenditure on research activities is recognised in the statement of profit and loss as incurred. Development expenditure is capitalised only if the expenditure can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable and the Company intends to complete development and to use or sell the asset.

• **Subsequent measurement**

Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates.

• **Amortisation**



**Annexure IV- Significant Accounting Policies to Restated Financial Statements**

Amortisation is calculated over the cost of the asset, or other amount substituted for cost. Amortisation is recognised in statement of profit and loss on a straight-line basis over the estimated useful lives of intangible assets from the date that they are available for use.

Class of asset	Useful lives considered (In years)
Trademark	5
Computer Software	5

• **Disposal**

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit and loss when the asset is derecognized.

**2.15 Provisions, contingent liabilities and contingent assets**

A provision is recognised when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value (except dismantling / decommissioning liabilities that are recognised as cost of Property, Plant and Equipment) and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not require an outflow of resources. When there is a possible obligation or a present obligation in respect of which likelihood of outflow of resources is remote, no provision or disclosure is made.

Contingent assets are neither disclosed nor recognised.

**2.16 Earnings per share**

Basic earnings per share are calculated by dividing the net profit or loss (after tax) for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The weighted average number of equity shares outstanding during the period is adjusted for events of rights issue and bonus issue.

Diluted earnings per share is calculated by dividing the net profit or loss (after tax) for the period attributable to equity shareholders and the weighted average number of equity shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

**2.17 Share issue expenses**

Share issue expenses are adjusted against securities premium (to the extent available) and statement of profit and loss. Pending issue of shares, same are shown under pre-paid expenses.



Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)  
CIN: U36994KA2017PLC105721

Annexure V- Notes to restated financial statements

(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

3 Share capital	As at	As at	As at	As at
	31 December 2023	31 March 2023	31 March 2022	31 March 2021
<b>Authorised capital</b> 2,50,000 (31 March 2023: 2,50,000, 31 March 2022: 2,50,000, 31 March 2021: 2,50,000) equity shares of INR 10 each	25.00	25.00	25.00	25.00
<b>Total</b>	<b>25.00</b>	<b>25.00</b>	<b>25.00</b>	<b>25.00</b>
<b>Issued, subscribed and fully paid-up</b> 50,000 (31 March 2023: 30,000, 31 March 2022: 30,000, 31 March 2021: 30,000) equity shares of INR 10 each	5.00	3.00	3.00	3.00
<b>Total</b>	<b>5.00</b>	<b>3.00</b>	<b>3.00</b>	<b>3.00</b>

3.1 Terms/ rights attached to equity shares

The Company has a single class of equity shares. All equity shares rank equally with regards to dividends and share in the Company's residual assets. The equity shareholders are entitled to receive dividend as declared from time to time. The voting rights of equity shareholders on a poll are in proportion to its share of the paid-up equity capital of the Company. Voting rights cannot be exercised in respect of shares on which any call or other sums presently payable has not been paid. Failure to pay any amount called up on shares may lead to forfeiture of the shares. On winding up of the Company, the holders of the equity shares will be entitled to receive the residual assets of the Company, remaining after distribution of all preferential amounts in proportion of the number of equity shares held.

3.2 The reconciliation of the number of shares outstanding and the amount of share capital as at 31 December 2023, 31 March 2023, 31 March 2022 and 31 March 2021 is set out below:

Particulars	31 December 2023		31 March 2023		31 March 2022		31 March 2021	
	Number of Shares	Amount	Number of Shares	Amount	Number of Shares	Amount	Number of Shares	Amount
Number of shares at the beginning	30,000	3.00	30,000	3.00	30,000	3.00	30,000	3.00
Add: Shares issued during the period/year (Refer note 3.5)	20,000	2.00	-	-	-	-	-	-
Less: Buyback during the period/year	-	-	-	-	-	-	-	-
Number of shares at the end	50,000	5.00	30,000	3.00	30,000	3.00	30,000	3.00

3.3 Equity shares held by each shareholder holding more than 5% shares

Particulars	As at 31 December 2023		As at 31 March 2023		As at 31 March 2022		As at 31 March 2021	
	% of holding	Number of Shares	% of holding	Number of Shares	% of holding	Number of Shares	% of holding	Number of Shares
Lalith Kumar*	0.00%	-	0.00%	-	33.33%	10,000	33.33%	10,000
Shashikala*	4.95%	2,475	33.33%	10,000	0.00%	-	0.00%	-
Tarun Gandhi	40.57%	20,285	33.33%	10,000	33.33%	10,000	33.33%	10,000
Anand Gandhi	40.57%	20,285	33.33%	10,000	33.33%	10,000	33.33%	10,000
	<b>86.09%</b>	<b>43,045</b>	<b>100.00%</b>	<b>30,000</b>	<b>100.00%</b>	<b>30,000</b>	<b>100.00%</b>	<b>30,000</b>

\* On demise of Mr. Lalith Kumar on 13 March 2021, his shares has been transferred to his spouse Mrs. Shashikala on 31 March 2022.

3.4 a) Disclosures of Shareholdings of Promoter and Promoter group is set out below:

Name	As at 31 December 2023		As at 31 March 2023		As at 31 March 2022		As at 31 March 2021	
	No. of Shares	% of total shares	No. of Shares	% of total shares	No. of Shares	% of total shares	No. of Shares	% of total shares
Lalith Kumar*	-	0.00%	-	0.00%	10,000	33.33%	10,000	33.33%
Shashikala*	2,475	4.95%	10,000	33.33%	-	0.00%	-	0.00%
Tarun Gandhi	20,285	40.57%	10,000	33.33%	10,000	33.33%	10,000	33.33%
Anand Gandhi	20,285	40.57%	10,000	33.33%	10,000	33.33%	10,000	33.33%
Isna Gandhi	2,475	4.95%	-	0.00%	-	0.00%	-	0.00%
Bhavika Gandhi	2,475	4.95%	-	0.00%	-	0.00%	-	0.00%
Bhavya Gandhi	505	1.01%	-	0.00%	-	0.00%	-	0.00%
	<b>48,500</b>	<b>97.00%</b>	<b>30,000</b>	<b>100.00%</b>	<b>30,000</b>	<b>100.00%</b>	<b>30,000</b>	<b>100.00%</b>

\* On demise of Mr. Lalith Kumar on 13 March 2021, his shares has been transferred to his spouse Mrs. Shashikala on 31 March 2022.



Annexure V- Notes to restated financial statements

(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

b) Change in % of Shareholdings of Promoter and Promoter group during the period/year

Name of the Promoter/Promoter group	% change from 31 March 2023 to 31 December 2023	% change from 31 March 2022 to 31 March 2023	% change from 31 March 2021 to 31 March 2022
Lalith Kumar*	0.00%	-33.33%	0.00%
Shashikala*	-28.38%	33.33%	0.00%
Tarun Gandhi	7.24%	0.00%	0.00%
Anand Gandhi	7.24%	0.00%	0.00%
Isha Gandhi	4.95%	0.00%	0.00%
Bhavika Gandhi	4.95%	0.00%	0.00%
Bhavya Gandhi	1.01%	0.00%	0.00%

\* Due to demise of Lalith Kumar on 13 March 2021, his shares has been transferred to shashikala on 31 March 2022.

3.5 Pursuant to the approval of the Board of Directors at their meeting dated 13 December 2023, the Company offered 20,000 fully paid up equity shares to the existing eligible shareholders on a right basis in the ratio of 2 (two) equity shares for every 3 (Three) equity shares held by them on the record date of 13 December 2023.

3.6 Changes in share capital subsequent to period end

- (a) Subsequent to period end, authorised share capital of the Company has been increased from 2,50,000 equity shares of Rs.10 each to 2,10,00,000 equity shares of Rs.10 each as approved by members at the extra ordinary general meeting held on 27 January 2024.
- (b) Subsequent to period end, pursuant to a resolution passed by the members at the extra ordinary general meeting held on 04 April 2024, the Company has issued and allotted 1,55,50,000 bonus equity shares in the ratio of 311 fully paid-up bonus shares of the face value of Rs. 10 each for every existing 1 fully paid-up equity share of the face value of Rs.10 each held by the members as on 04 April 2024 (the Record Date). The bonus equity shares has been issued on 05 April 2024 by capitalizing the sum of Rs.1,555.00 from and out of free reserves of the Company.

4 Reserves and surplus	As at	As at	As at	As at
	31 December 2023	31 March 2023	31 March 2022	31 March 2021
<b>Surplus of Statement of Profit and Loss</b>				
As per the last Balance Sheet	457.23	145.79	(111.58)	(11.78)
Add: Restated net profit/(loss) for the period/ year transferred from Restated Statement of Profit and Loss	1,100.40	311.44	257.37	(99.80)
<b>Total</b>	<b>1,557.63</b>	<b>457.23</b>	<b>145.79</b>	<b>(111.58)</b>

5 Long-term provisions	As at	As at	As at	As at
	31 December 2023	31 March 2023	31 March 2022	31 March 2021
<b>Provision for employee benefits</b>				
- Gratuity (Refer note 31.2 and note 37)	29.38	26.85	14.50	8.51
<b>Total</b>	<b>29.38</b>	<b>26.85</b>	<b>14.50</b>	<b>8.51</b>

6 Short term borrowing	As at	As at	As at	As at
	31 December 2023	31 March 2023	31 March 2022	31 March 2021
<b>Unsecured</b>				
- From related parties (Refer note 6.1 and note 30)	-	3.50	12.11	12.11
<b>Total</b>	<b>-</b>	<b>3.50</b>	<b>12.11</b>	<b>12.11</b>

6.1 Unsecured loans from related parties are in the nature of current account transactions, repayable on demand and in accordance with the terms of agreement and also interest free.

7 Trade payables	As at	As at	As at	As at
	31 December 2023	31 March 2023	31 March 2022	31 March 2021
Amount due to micro, small and medium enterprises (Refer note 7.1)	107.74	303.51	11.01	141.90
Amount due to other than micro, small and medium enterprises	11.01	18.72	0.16	94.07
Amount due to related party (Refer Note 30)	0.45	196.17	232.03	270.95
<b>Total</b>	<b>119.20</b>	<b>518.40</b>	<b>243.20</b>	<b>506.92</b>



Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)  
CIN: U36994KA2017PLC105721

**Annexure V- Notes to restated financial statements**

(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

**7.1 Disclosure u/s 22 of Micro, Small and Medium Enterprises Development Act, 2006**

Disclosure of outstanding dues to vendors registered with appropriate authority under the Micro, Small and Medium Enterprises Development Act, 2006 is to the extent of information available with the Company. Disclosure required under the Act are as given below.

Particulars	As at	As at	As at	As at
	31 December 2023	31 March 2023	31 March 2022	31 March 2021
a) the principal amount and the interest due thereon (to be shown separately) remaining unpaid to any supplier at the end of each accounting period/year				
(i) Principal	107.74	303.51	11.01	141.90
(ii) Interest	4.38	-	-	-
b) the amount of interest paid by the buyer in terms of section 16 of the Micro, Small and Medium Enterprises Development Act, 2006, along with the amount of the payment made to the supplier beyond the appointed day during each accounting period/year	-	-	-	-
c) the amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006	-	-	-	-
d) the amount of interest accrued and remaining unpaid at the end of each accounting period/year	4.38	-	-	-
e) the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Micro, Small and Medium Enterprises Development Act, 2006	-	-	-	-

Note: The Company has disclosed the suppliers who have registered themselves under "Micro, Small and Medium Enterprises Development Act, 2006" to the extent they have identified on the basis of information available with the Company.

**7.2 Trade payable ageing**

Particulars	As at	As at	As at	As at
	31 December 2023	31 March 2023	31 March 2022	31 March 2021
<b>Micro, small and medium enterprises</b>				
- Less than 1 year	107.56	303.51	11.01	141.90
- 1-2 years	0.18	-	-	-
- 2-3 years	-	-	-	-
- More than 3 years	-	-	-	-
<b>Total</b>	<b>107.74</b>	<b>303.51</b>	<b>11.01</b>	<b>141.90</b>
<b>Others</b>				
- Less than 1 year	11.46	25.17	0.16	360.52
- 1-2 years	-	107.71	232.03	4.50
- 2-3 years	-	82.01	-	-
- More than 3 years	-	-	-	-
<b>Total</b>	<b>11.46</b>	<b>214.89</b>	<b>232.19</b>	<b>365.02</b>

8 Other current liabilities	As at	As at	As at	As at
	31 December 2023	31 March 2023	31 March 2022	31 March 2021
Other accrued liabilities	17.40	0.30	0.24	4.10
Employee related payables (Refer note 30)	27.25	188.76	183.24	212.40
Bank balance - book overdrawn	-	-	-	60.04
Statutory dues	129.82	41.06	53.31	131.66
Other liabilities	0.02	0.27	3.33	1.82
<b>Total</b>	<b>174.49</b>	<b>230.39</b>	<b>240.12</b>	<b>410.02</b>

9 Short-term provisions	As at	As at	As at	As at
	31 December 2023	31 March 2023	31 March 2022	31 March 2021
Provision for employee benefits				
- Gratuity (Refer note 31.2 and note 37)	2.32	0.06	0.03	0.01
Provision for income tax (net)	126.32	-	-	-
<b>Total</b>	<b>128.64</b>	<b>0.06</b>	<b>0.03</b>	<b>0.01</b>



Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)  
 CIN: U36944KA2017PLC105721  
 Annexure V- Notes to related financial statements  
 (All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

10 Property, plant and equipment

Description	Computers	Office equipments	Furniture and fixtures	Vehicles (Refer note 10.1)	Electrical Fittings	Plant and Machinery	Total Owned assets
<b>Gross block</b>							
Balance as at 1 April 2020	-	0.08	-	-	-	-	0.08
Additions	1.61	43.18	3.17	23.51	0.82	-	72.29
Disposals/transferred	-	(39.90)	-	-	-	39.90	-
Re-classification (Refer note 10.2)	-	3.37	3.17	23.51	0.82	-	72.39
Balance as at 31 March 2021	1.61	6.35	6.34	47.02	1.64	-	63.06
Additions	1.61	3.37	3.17	23.51	0.82	39.90	72.38
Disposals/transferred	6.25	-	-	-	-	3.57	9.82
Balance as at 31 March 2022	7.86	3.37	3.17	23.51	0.82	24.82	63.55
Balance as at 1 April 2022	7.86	3.37	3.17	23.51	0.82	24.82	63.55
Additions	-	4.23	0.29	26.95	-	-	31.47
Disposals/transferred	-	-	-	-	-	-	-
Balance as at 31 March 2023	7.86	7.60	3.46	50.46	0.82	24.82	95.02
Balance as at 1 April 2023	7.86	7.60	3.45	50.45	0.82	24.82	95.02
Additions	0.68	1.31	-	2.66	-	24.78	29.43
Disposals/transferred	-	-	-	(5.69)	-	-	(5.69)
Balance as at 31 December 2023	8.53	8.91	3.45	47.43	0.82	49.60	118.75
<b>Accumulated depreciation</b>							
Balance as at 1 April 2020	-	-	-	-	-	-	-
Depreciation for the year	0.09	0.52	0.01	0.02	0.00	-	0.64
Deductions	-	-	-	-	-	-	-
Balance as at 31 March 2021	0.09	0.47	0.01	0.02	0.00	0.05	0.64
Balance as at 1 April 2021	0.09	0.47	0.01	0.02	0.00	0.05	0.64
Depreciation for the year	3.50	1.37	0.81	7.22	0.21	16.00	26.11
Deductions	-	-	-	-	-	(4.88)	(4.88)
Balance as at 31 March 2022	3.59	1.84	0.82	7.24	0.21	11.17	24.87
Balance as at 1 April 2022	3.59	1.84	0.82	7.24	0.21	11.17	24.87
Depreciation for the year	2.70	1.52	0.66	10.31	0.16	6.15	21.20
Deductions	-	-	-	-	-	-	-
Balance as at 31 March 2023	6.29	3.36	1.48	17.25	0.37	17.32	46.07



Anwill Health Care Limited (Formerly Known as Anwill Health Care Private Limited)  
 CIN: U36994KA2017PLC105721  
 Annexure V: Notes to restated financial statements  
 (All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

Property, plant and equipment (Contd.)

Description	Computers	Office equipments	Furniture and fixtures	Vehicles (Refer note 10.1)	Electrical Fittings	Plant and Machinery	Total Owned assets
Balance as at 1 April 2023	6.29	3.36	1.48	17.25	0.37	17.32	46.07
Depreciation for the year	0.82	1.59	0.39	7.49	0.09	4.35	14.73
Deductions	-	-	-	(3.01)	-	-	(3.01)
<b>Balance as at 31 December 2023</b>	<b>7.11</b>	<b>4.95</b>	<b>1.87</b>	<b>21.73</b>	<b>0.46</b>	<b>21.67</b>	<b>57.79</b>
<b>Net block</b>							
As At 31 March 2021	1.52	2.80	3.16	23.49	0.82	28.85	71.74
As At 31 March 2022	4.26	1.53	2.35	16.27	0.61	19.65	36.67
As At 31 March 2023	1.57	4.24	1.98	33.21	0.45	7.50	46.95
As At 31 December 2023	1.42	3.96	1.99	25.69	0.35	27.92	60.94

10.1 Net block of vehicles includes Rs. 6.48 as at 31 December 2023 (31 March 2023: Rs. 8.46 31 March 2022: Rs. 12.27 and 31 March 2021: Rs. 17.80) which is in the name of the director of the Company. Process of transfer in the of the Company is in progress.

10.2 The Laser machines have been re-classified from office equipments to Plant and Machinery.

10.3 The amount of capital commitment is disclosed in note 35.1

11: Intangible assets

Description	Trademarks	Software	Total
<b>Gross block</b>			
Balance as at 1 April 2020	-	-	-
Additions during the year	7.59	0.44	8.03
<b>Balance as at 31 March 2021</b>	<b>7.59</b>	<b>0.44</b>	<b>8.03</b>
Balance as at 1 April 2021	7.59	0.44	8.03
Additions during the year	-	1.25	1.25
<b>Balance as at 31 March 2022</b>	<b>7.59</b>	<b>1.69</b>	<b>9.28</b>
Balance as at 1 April 2022	7.59	1.69	9.28
Additions during the year	-	-	-
<b>Balance as at 31 March 2023</b>	<b>7.59</b>	<b>1.69</b>	<b>9.28</b>
Balance as at 1 April 2023	7.59	1.69	9.28
Additions during the year	0.82	-	0.82
<b>Balance as at 31 December 2023</b>	<b>8.41</b>	<b>1.69</b>	<b>10.10</b>
<b>Amortisation</b>			
Balance as at 1 April 2020	-	-	-
Amortisation for the year	0.01	0.00	0.01
<b>Balance as at 31 March 2021</b>	<b>0.01</b>	<b>0.00</b>	<b>0.01</b>





Amwill Health Care Limited (Formerly known as: Amwill Health Care Private Limited)  
 CIN: U36594KA2017PLC105721  
 Annexure V- Notes to restated financial statements  
 (All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

Intangible assets (Contd.)

Description	Trademarks	Software	Total
Balance as at 1 April 2021	0.01	0.00	0.01
Amortisation for the year	3.42	0.22	3.64
<b>Balance as at 31 March 2022</b>	<b>3.43</b>	<b>0.22</b>	<b>3.65</b>
Balance as at 1 April 2022	3.43	0.22	3.65
Amortisation for the year	1.88	0.66	2.54
<b>Balance as at 31 March 2023</b>	<b>5.31</b>	<b>0.88</b>	<b>6.19</b>
Balance as at 1 April 2023	5.31	0.88	6.19
Amortisation for the year	1.06	0.27	1.33
<b>Balance as at 31 December 2023</b>	<b>6.36</b>	<b>1.16</b>	<b>7.52</b>
Net block			
As At 31 March 2021	7.58	0.44	8.02
As At 31 March 2022	4.16	1.47	5.63
As At 31 March 2023	2.29	0.81	3.10
As At 31 December 2023	2.05	0.53	2.58

11.1 Software is other than internally generated software.

11.2 The Company has not revalued its Intangible assets

12 Capital work-in-progress

Description	Office Equipment
Balance as at 1 April 2020	-
Additions	-
Capitalised during the year	-
<b>Balance as at 31 March 2021</b>	<b>-</b>
Balance as at 1 April 2021	-
Additions	-
Capitalised during the year	-
<b>Balance as at 31 March 2022</b>	<b>-</b>
Balance as at 1 April 2022	-
Additions	-
Capitalised during the year	-
<b>Balance as at 31 March 2023</b>	<b>-</b>
Balance as at 1 April 2023	-
Additions	21.25
Capitalised during the year	-
<b>Balance as at 31 December 2023</b>	<b>21.25</b>



12.1 Ageing schedule for Capital-work-in-progress:

Ageing	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
<b>As at 31 Dec 2023</b>					
Projects in progress	21.25	-	-	-	21.25
Projects temporarily suspended	-	-	-	-	-
<b>As at 31 March 2023</b>					
Projects in progress	-	-	-	-	-
Projects temporarily suspended	-	-	-	-	-
<b>As at 31 March 2022</b>					
Projects in progress	-	-	-	-	-
Projects temporarily suspended	-	-	-	-	-
<b>As at 31 March 2021</b>					
Projects in progress	-	-	-	-	-
Projects temporarily suspended	-	-	-	-	-

Note: There are no projects under Capital Work in progress where the completion is overdue or has exceeded its cost compared to its original plan.

13 Intangible Assets under development :

Description	Trademarks
Balance as at 1 April 2020	-
Additions	-
Capitalised during the year	-
<b>Balance as at 31 March 2021</b>	-
Balance as at 1 April 2021	-
Additions	-
Capitalised during the year	-
<b>Balance as at 31 March 2022</b>	-
Balance as at 1 April 2022	-
Additions	-
Capitalised during the year	-
<b>Balance as at 31 March 2023</b>	-
Balance as at 1 April 2023	17.65
Additions	-
Capitalised during the year	-
<b>Balance as at 31 December 2023</b>	<b>17.65</b>

13.1 Ageing schedule of intangible assets under development:

Ageing	As at 31 Dec 2023	As at 31 March 2023	As at 31 March 2022	As at 31 March 2021
Less than 1 Year	17.65	-	-	-
1-2 Years	-	-	-	-
2-3 Years	-	-	-	-
More than 3 Years	-	-	-	-
<b>Total</b>	<b>17.65</b>	-	-	-



Annexure V- Notes to restated financial statements

(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

14	Deferred tax assets (net)	As at 31 December 2023	As at 31 March 2023	As at 31 March 2022	As at 31 March 2021
	<b>Deferred tax assets</b>				
	Difference in net carrying value of property, plant and equipment and intangible assets as per income tax and books	7.71	7.30	4.85	1.38
	Expense allowed on payment basis as per Income tax act, 1961	1.20	3.12	1.37	1.95
	<b>Total</b>	<b>8.91</b>	<b>10.42</b>	<b>6.22</b>	<b>3.33</b>
15	Long term loans and advances (Unsecured, considered good except otherwise stated)	As at 31 December 2023	As at 31 March 2023	As at 31 March 2022	As at 31 March 2021
	Security deposits	4.99	4.99	4.36	2.66
	<b>Total</b>	<b>4.99</b>	<b>4.99</b>	<b>4.36</b>	<b>2.66</b>
16	Other non-current assets (Unsecured, considered good except otherwise stated)	As at 31 December 2023	As at 31 March 2023	As at 31 March 2022	As at 31 March 2021
	Income tax assets (net)	-	33.58	44.02	20.48
	<b>Total</b>	<b>-</b>	<b>33.58</b>	<b>44.02</b>	<b>20.48</b>
17	Inventories	As at 31 December 2023	As at 31 March 2023	As at 31 March 2022	As at 31 March 2021
	Material in hand	104.63	317.96	205.76	249.50
	<b>Total</b>	<b>104.63</b>	<b>317.96</b>	<b>205.76</b>	<b>249.50</b>

17.1 Inventories are valued at cost or net realizable value whichever is lower. Refer note 2.10 for detailed accounting policy for inventory valuation.



Anwill Health Care Limited (Formerly known as Anwill Health Care Private Limited)  
CIN: U36994KA2017PLC105721

**Annexure V- Notes to restated financial statements**

(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

18 Trade receivable (Unsecured, considered good unless otherwise stated)	As at	As at	As at	As at
	31 December 2023	31 March 2023	31 March 2022	31 March 2021
(From the date they are due for payment)				
Outstanding for a period exceeding six months	3.82	4.26	-	0.03
Other debts	799.41	118.94	87.53	441.34
<b>Total</b>	<b>803.23</b>	<b>123.20</b>	<b>87.53</b>	<b>441.37</b>

18.1 Trade receivable includes receivable from related party (Amderma Healthcare LLP) amounting to Rs. 786.22 (As at 31 March 2023: Rs. 103.61, As at 31 March 2022: Rs. 63.71 and As at 31 March 2021: Rs. 328.59) in which directors of the Company are partners (Also refer note 30).

18.2 There are no unbilled receivables, hence the same is not disclosed in the ageing schedule.

**18.3 Trade receivable ageing**

Particulars	As at	As at	As at	As at
	31 December 2023	31 March 2023	31 March 2022	31 March 2021
<b>Undisputed trade receivables-considered good</b>				
- Less than 6 months	799.41	118.94	87.53	441.34
- 6 Months - 1 year	3.41	3.64	-	0.03
- 1-2 years	0.41	0.62	-	-
- 2-3 years	-	-	-	-
- More than 3 years	-	-	-	-
<b>Sub-total</b>	<b>803.23</b>	<b>123.20</b>	<b>87.53</b>	<b>441.37</b>
<b>Disputed trade receivables - considered good</b>				
- Less than 6 months	-	-	-	-
- 6 Months - 1 year	-	-	-	-
- 1-2 years	-	-	-	-
- 2-3 years	-	-	-	-
- More than 3 years	-	-	-	-
<b>Sub-total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total of trade receivable</b>	<b>803.23</b>	<b>123.20</b>	<b>87.53</b>	<b>441.37</b>

19 Cash and bank balance	As at	As at	As at	As at
	31 December 2023	31 March 2023	31 March 2022	31 March 2021
<b>A. Cash and cash equivalents</b>				
Cash on hand	8.92	8.65	7.53	4.88
Balance with bank in current accounts	444.93	2.09	233.27	-
Fixed deposits with bank- Sweep-in facility	291.85	573.30	-	-
<b>Sub total (A)</b>	<b>745.70</b>	<b>584.04</b>	<b>240.80</b>	<b>4.88</b>
<b>B. Other bank balance</b>				
Fixed deposits with bank (maturity period more than three months but less than twelve months)	102.85	101.32	-	-
<b>Sub total (B)</b>	<b>102.85</b>	<b>101.32</b>	<b>-</b>	<b>-</b>
<b>Total</b>	<b>848.55</b>	<b>685.36</b>	<b>240.80</b>	<b>4.88</b>

20 Short-term loans and advances (Unsecured, considered good except otherwise stated)	As at	As at	As at	As at
	31 December 2023	31 March 2023	31 March 2022	31 March 2021
Advance to vendors	47.42	3.99	21.43	6.19
Advance to employees (Refer note 20.1 and note 30)	79.10	1.53	4.30	4.42
<b>Total</b>	<b>126.52</b>	<b>5.52</b>	<b>25.73</b>	<b>10.61</b>


20.1 Advances to employees also includes Rs. 45.16 (31 March 2023: Nil, 31 March 2022: Nil and 31 March 2021: Nil) interest free advance given to directors against salary in accordance with employee advance policy of the Company. These are adjusted against monthly salary in accordance with policy of the Company.

21 Other current assets (Unsecured, considered good except otherwise stated)	As at	As at	As at	As at
	31 December 2023	31 March 2023	31 March 2022	31 March 2021
Balance with government authorities	-	-	-	16.40
- GST input credit receivable	-	-	-	-
Prepaid expenses (Refer note 21.1)	12.54	0.18	0.03	-
Interest accrued on fixed deposits	2.55	6.17	-	-
<b>Total</b>	<b>15.09</b>	<b>6.35</b>	<b>0.03</b>	<b>16.40</b>

21.1 The above includes expenses in relation to proposed Initial Public Offering aggregating to Rs. 11.00 (31 March 2023: Nil, 31 March 2022: Nil and 31 March 2021: Nil) which would be first adjusted against the security premium (if available) or charged to statement of profit and loss in accordance with accounting policy of the Company. In case of offer for sale by existing shareholders, proportionate IPO expenses will be recovered from selling shareholders.



22	Revenue from operations	For the period ended 31 December 2023	Year ended 31 March 2023	Year ended 31 March 2022	Year ended 31 March 2021
	Sale of products (net of Goods and Service tax) (Refer note 30 and note 33)	3,578.83	3,016.63	2,761.32	1,799.94
	<b>Total</b>	<b>3,578.83</b>	<b>3,016.63</b>	<b>2,761.32</b>	<b>1,799.94</b>
23	Other income	For the period ended 31 December 2023	Year ended 31 March 2023	Year ended 31 March 2022	Year ended 31 March 2021
	Interest income on				
	- Deposits with bank	23.24	9.98	0.22	-
	- Income tax refund	0.34	1.64	-	-
	Profit on sale of property, plant and equipment	2.78	-	-	-
	<b>Total</b>	<b>26.36</b>	<b>11.62</b>	<b>0.22</b>	<b>-</b>
24	Materials produced	For the period ended 31 December 2023	Year ended 31 March 2023	Year ended 31 March 2022	Year ended 31 March 2021
	Materials produced during the period/year	754.30	1,019.04	833.33	1,052.47
	<b>Total</b>	<b>754.30</b>	<b>1,019.04</b>	<b>833.33</b>	<b>1,052.47</b>
25	Changes in inventories of materials in hand	For the period ended 31 December 2023	Year ended 31 March 2023	Year ended 31 March 2022	Year ended 31 March 2021
	Inventories at the beginning of the period / year	317.96	205.76	249.50	-
	Inventories at the end of the period / year	104.63	317.96	205.76	249.50
	<b>Decrease / (Increase) in inventories of materials in hand</b>	<b>213.33</b>	<b>(112.20)</b>	<b>43.74</b>	<b>(249.50)</b>
26	Employee benefits expenses	For the period ended 31 December 2023	Year ended 31 March 2023	Year ended 31 March 2022	Year ended 31 March 2021
	Salaries and wages (Refer note 30)	381.17	690.14	626.54	372.94
	Contribution to provident and other funds				
	- Provident fund (Refer note 31.1)	25.73	40.40	4.70	3.12
	- Other fund (Refer note 31.1)	0.01	0.01	-	-
	Gratuity expenses (Refer note 31.2 and note 37)	4.78	12.39	6.01	9.52
	Staff welfare charges	7.60	4.87	1.92	0.61
	<b>Total</b>	<b>420.29</b>	<b>747.81</b>	<b>639.17</b>	<b>385.19</b>
27	Finance cost	For the period ended 31 December 2023	Year ended 31 March 2023	Year ended 31 March 2022	Year ended 31 March 2021
	Other borrowing cost	4.38	-	-	-
	<b>Total</b>	<b>4.38</b>	<b>-</b>	<b>-</b>	<b>-</b>



Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)  
CIN: U36994KA2017PLC105721

Annexure V- Notes to restated financial statements

(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

28 Depreciation and amortisation expense	For the period ended	Year ended	Year ended	Year ended
	31 December 2023	31 March 2023	31 March 2022	31 March 2021
Depreciation of property, plant and equipment (Refer note 10)	14.73	21.21	29.11	0.64
Amortization of intangible assets (Refer note 11)	1.33	2.54	3.64	0.01
<b>Total</b>	<b>16.06</b>	<b>23.75</b>	<b>32.75</b>	<b>0.65</b>

29 Other expenses	For the period ended	Year ended	Year ended	Year ended
	31 December 2023	31 March 2023	31 March 2022	31 March 2021
Postage, telegrams and telephone charges	0.16	0.22	0.14	0.02
Power and fuel	3.87	4.15	0.69	0.03
Printing and stationery	9.56	8.49	0.96	0.09
Rent expenses	5.36	7.14	6.78	2.68
Rates and taxes	0.09	0.02	11.17	-
Repair and maintenance				
- Computer and software maintenance	1.12	1.31	0.92	10.43
- Others	1.33	3.27	0.27	0.03
General office and other expenses	1.66	18.12	48.32	9.66
Advertisement and sales promotion	301.00	293.25	223.36	316.35
Discount allowed (Net) (Refer note 30)	175.29	172.01	140.87	76.66
Commission expenses (Refer note 30)	155.63	244.08	130.27	146.42
Conveyance and marketing expenses	30.34	33.47	34.80	15.91
Expired goods written off	3.09	4.90	41.12	-
Freight outward	2.42	1.68	2.47	1.35
Insurance	0.79	0.04	0.78	-
License and registration fees	0.33	0.38	-	-
Legal and professional fees (Refer note 30)	20.83	130.10	223.69	133.12
Loss on sale of property, plant and equipment	-	-	8.77	-
Bad debts written off	0.05	4.58	-	-
Audit remuneration (Refer note 29.1)	6.75	5.20	3.70	1.50
<b>Total</b>	<b>719.67</b>	<b>932.41</b>	<b>879.08</b>	<b>714.25</b>

29.1 Audit remuneration*	For the period ended	Year ended	Year ended	Year ended
	31 December 2023	31 March 2023	31 March 2022	31 March 2021
Audit fees				
Statutory audit fees	6.75	4.20	3.70	1.50
Tax audit fees	-	1.00	-	-
<b>Total</b>	<b>6.75</b>	<b>5.20</b>	<b>3.70</b>	<b>1.50</b>

\*Excluding goods and service tax



Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)  
 CIN: U36994KA2017PLC105721  
 Annexure V- Notes to restated financial statements  
 (All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

30 Related party disclosures

(i) Name and relationships of related parties:

(i) Key Management Personnel ('KMP')

Mr. Tarun Gandhi – Director (upto 27 January 2024) and Managing Director (w.e.f. 27 January 2024)  
 Mr. Anand Gandhi – Director (upto 27 January 2024) and Managing Director (w.e.f. 27 January 2024)  
 Mr. Lalith Kumar – Director (upto 13 March 2021 i.e. on demise)  
 Dr. Rekha Jagadish - Non Executive Director (w.e.f. 28 December 2023)  
 Ms. Sharanya Nagaraj- Chief financial officer (w.e.f. 25 January 2024)  
 Ms. Sapna Parmar- Company Secretary (w.e.f. 25 January 2024)

(ii) Independent Directors

Mr. Sagar Goutam Nahar- Independent Director (w.e.f. 27 January 2024)  
 Mr. Sambhav Mehta- Independent Director (w.e.f. 27 January 2024)

(iii) Relatives of Key Management Personnel ('KMP')

(only where there are transactions)

Mrs. Shashikala - Mother of Managing Director  
 Mr. Lalith Kumar - Father of Managing Director  
 Mrs. Isha Gandhi - Spouse of Managing Director  
 Mrs. Bhavika Gandhi - Spouse of Managing Director  
 Mrs. Bhavya Gandhi - Sister of Managing Director

(iv) Enterprise over which the Key Management Personnel have significant influence

(only where there are transactions/balances)

Amderma Healthcare LLP  
 Ample Pharma

(ii) Transactions with related parties.

Nature of transactions	Name of Party	For the period ended 31 December 2023	Year ended 31 March 2023	Year ended 31 March 2022	Year ended 31 March 2021
Sale of goods	Amderma Healthcare LLP	3,543.62	2,963.58	2,489.43	1,641.11
	Ample Pharma	-	0.11	8.90	5.34
Discount Allowed (net)	Amderma Healthcare LLP	175.34	171.94	141.30	77.05
Commission expense (net)	Amderma Healthcare LLP	7.10	7.87	-	37.00
Reimbursement of expenses	Amderma Healthcare LLP	1.67	0.28	-	-
	Ample Pharma	0.11	0.51	1.96	0.05
Remuneration paid	Anand Gandhi	71.08	185.70	180.00	-
	Tarun Gandhi	71.08	185.70	180.00	162.00
	Lalith Kumar	-	-	-	162.00
Salary paid	Shashikala	31.49	56.25	17.72	-
	Isha Gandhi	31.49	65.25	45.00	-
	Bhavika Gandhi	31.49	65.25	45.00	-
Advance salary paid	Anand Gandhi	22.58	-	-	-
	Tarun Gandhi	22.58	-	-	-
	Shashikala	9.38	-	-	-
	Isha Gandhi	9.38	-	-	-
	Bhavika Gandhi	9.38	-	-	-
Repayment of unsecured loans	Anand Gandhi	0.00	5.81	-	0.15
	Tarun Gandhi	-	5.31	0.66	0.15
	Lalith Kumar	-	-	-	0.15
	Shashikala	3.50	-	-	-
Proceeds from unsecured loans	Anand Gandhi	-	1.67	-	2.80
	Tarun Gandhi	-	0.85	0.66	3.12
	Lalith Kumar	-	-	-	2.15
	Bhavika Gandhi	-	-	-	-
Professional fees	Anand Gandhi	8.00	48.00	48.00	49.50
	Tarun Gandhi	8.00	48.00	48.00	36.00
	Lalith Kumar	-	-	-	27.00
	Bhavika Gandhi	4.50	6.61	-	-

(iii) Related party outstanding balances

Nature of Balance	Name of Party	As at 31 December 2023	As at 31 March 2023	As at 31 March 2022	As at 31 March 2021
Remuneration payable	Anand Gandhi	-	-	-	-
	Tarun Gandhi	-	16.70	16.70	103.87
	Shashikala*	-	127.86	110.30	103.87
	Isha Gandhi	-	9.52	18.31	-
	Bhavika Gandhi	-	9.52	18.31	-
Advance salary	Anand Gandhi	22.58	-	-	-
	Tarun Gandhi	22.58	-	-	-
	Shashikala*	9.38	-	-	-
	Isha Gandhi	9.38	-	-	-
	Bhavika Gandhi	9.38	-	-	-
Trade receivable	Amderma Healthcare LLP	766.22	103.61	63.71	328.59
Other payables	Ample Pharma	-	-	-	-
Other payables	Anand Gandhi	-	4.04	91.21	91.21
Reimbursement payable	Ample Pharma	-	0.51	-	55.43
Unsecured loans	Anand Gandhi	-	0.00	4.15	4.15
	Tarun Gandhi	-	-	4.46	4.46
Professional fees payable	Shashikala*	-	3.50	3.50	3.50
	Anand Gandhi	-	88.71	19.36	54.70
	Tarun Gandhi	-	67.43	91.62	39.78
	Shashikala*	-	29.55	29.84	29.84
	Bhavika Gandhi	0.45	5.94	-	-

\*Outstanding liabilities transferred to Mrs. Shashikala (Wife - legal heir) on demise of Mr. Lalith Kumar.



Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)  
CIN: U36994KA2017PLC105721

**Annexure V- Notes to restated financial statements**

(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

(iv) As at 31 December 2023, the Company has not granted any loans to the promoters, directors, KMPs and the related parties (as defined under Companies Act, 2013) either severally or jointly with any other person (31 March 2023: Nil; 31 March 2022: Nil; 31 March 2021: Nil). Loans given to employees as per the Company's policy are not considered for the purposes of disclosure under Section 186(4) of the Companies Act, 2013.

(v) Transaction with related parties are disclosed from the date when relationship came into existence and upto the date of relationship existed.

**31 Employee Benefit Obligations**

**31.1 Disclosures for defined contribution plan**

The Company has certain defined contribution plans. The obligation of the Company is limited to the amount contributed and it has no further contractual obligation. Following are the details regarding Company's contributions made during the period/year:

Particulars	For the period ended 31 December 2023	Year ended 31 March 2023	Year ended 31 March 2022	Year ended 31 March 2021
Provident fund and pension fund	26.73	40.40	4.70	3.12
Karnataka labour welfare fund (KLWF)	0.01	0.01	-	-
<b>Total</b>	<b>26.74</b>	<b>40.41</b>	<b>4.70</b>	<b>3.12</b>

**31.2 Disclosures for defined benefit plans**

(i) **Gratuity**

In accordance with the Payment of Gratuity Act, 1972, the Company provides for gratuity, a defined benefit retirement plan ("the Plan") covering eligible employees. The Plan provides for a lump sum payment to vested employees on retirement, death, apacitation or termination of employment of amounts that are based on salary and tenure of employment. Liabilities with regard to the Gratuity Plan are determined by actuarial valuation using Projected Unit Credit method. The Gratuity plan is non-funded.

The actuarial assumptions used in estimation of actuarial liability for the Gratuity Plan were as follows:

Particulars	For the period ended 31 December 2023	Year ended 31 March 2023	Year ended 31 March 2022	Year ended 31 March 2021
Discount rate (per annum)	7.41%	7.39%	7.26%	6.79%
Salary Escalation (per annum)	8.00%	8.00%	8.00%	8.00%
Attrition Rate (per annum)	6.00%	5.00%	6.00%	6.00%
Mortality Rate	100% of Indian Assured Lives Mortality (2012-14)			

The following table sets out the funded status of the Gratuity Plan and the amounts recognized in the financial statements:

Changes in the present value of obligations	As at 31 December 2023	As at 31 March 2023	As at 31 March 2022	As at 31 March 2021
Liability at the beginning of the year	26.92	14.52	8.52	-
Current service cost	6.13	13.91	10.81	8.33
Interest cost	1.49	1.05	0.58	-
Actuarial (gain)/loss on obligations	(2.85)	(2.58)	(5.38)	-
Past service cost	-	-	-	0.18
Benefits paid	-	-	-	-
<b>Liability at the end of the period/ year</b>	<b>31.69</b>	<b>26.92</b>	<b>14.52</b>	<b>8.52</b>
- Non-current portion of defined benefit obligation	29.38	26.65	14.50	8.51
- Current portion of defined benefit obligation	2.32	0.06	0.03	0.01

Table of recognition of actuarial gain / loss	For the period ended 31 December 2023	Year ended 31 March 2023	Year ended 31 March 2022	Year ended 31 March 2021
Actuarial (gain)/ loss on obligation for the period	(2.85)	(2.58)	(5.38)	-
Actuarial gain/ (loss) on assets for the period	-	-	-	-
<b>Actuarial (gain)/ loss recognized in Statement of Profit and Loss</b>	<b>(2.85)</b>	<b>(2.58)</b>	<b>(5.38)</b>	<b>-</b>

Breakup of actuarial (gain) /loss	For the period ended 31 December 2023	Year ended 31 March 2023	Year ended 31 March 2022	Year ended 31 March 2021
Actuarial loss/(gain) arising from change in demographic assumption	0.97	0.28	-	-
Actuarial loss arising from change in financial assumption	(0.06)	(0.39)	(0.41)	-
Actuarial loss/(gain) arising from experience	(3.76)	(2.47)	(4.97)	-
<b>Total</b>	<b>(2.85)</b>	<b>(2.58)</b>	<b>(5.38)</b>	<b>-</b>

Amount recognized in the Balance Sheet	As at 31 December 2023	As at 31 March 2023	As at 31 March 2022	As at 31 March 2021
Liability at the end of the period	31.69	26.92	14.52	8.52
Fair value of plan assets at the end of the period	-	-	-	-
<b>Total</b>	<b>31.69</b>	<b>26.92</b>	<b>14.52</b>	<b>8.52</b>





Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)  
CIN: U36994KA2017PLC105721

Annexure V- Notes to restated financial statements

(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

Expenses recognized in the statement of profit and loss	For the period ended 31 December 2023	Year ended 31 March 2023	Year ended 31 March 2022	Year ended 31 March 2021
Service cost	6.13	13.91	10.81	8.33
Interest cost	1.49	1.05	0.58	-
Past service cost	-	-	-	0.18
Actuarial loss/(gain)	(2.85)	(2.58)	(5.38)	-
<b>Expenses recognised in the Statement of Profit or Loss</b>	<b>4.78</b>	<b>12.39</b>	<b>6.01</b>	<b>8.52</b>

Sensitivity analysis of benefit obligation (Gratuity)	As at 31 December 2023	As at 31 March 2023	As at 31 March 2022	As at 31 March 2021
<b>a) Impact of change in discount rate</b>				
Present value of obligation at the end of the period				
a) Impact due to increase of 0.50%	(1.39)	(1.61)	(0.88)	(0.31)
b) Impact due to decrease of 0.50%	1.50	1.76	0.96	0.34
<b>b) Impact of change in salary growth</b>				
Present value of obligation at the end of the period				
a) Impact due to increase of 0.50%	0.74	0.92	0.58	0.21
b) Impact due to decrease of 0.50%	(0.68)	(0.90)	(0.55)	(0.21)

Pay-out analysis	As at 31 December 2023	As at 31 March 2023	As at 31 March 2022	As at 31 March 2021
Expected Outgo First	2.32	0.06	0.03	0.01
Expected Outgo Second	1.19	0.05	0.04	0.01
Expected Outgo Third	1.59	0.06	0.08	0.01
Expected Outgo Fourth	2.08	1.22	0.41	0.05
Expected Outgo Fifth	1.48	2.48	0.74	3.29
Expected Outgo Sixth	1.39	1.06	0.83	0.22
Expected Outgo 6 years and above	21.64	21.99	12.40	4.92

32 Earning Per Share

Particulars	For the period ended 31 December 2023	Year ended 31 March 2023	Year ended 31 March 2022	Year ended 31 March 2021
Restated net profit/(loss) after tax	1,100.40	311.44	257.37	(99.80)
Weighted average number of equity shares in calculating basic and diluted EPS (Refer note 32.1 and note 32.2)	1,55,99,940	1,55,96,668	1,55,96,668	1,55,96,668
Face value of share in rupees	10	10	10	10
Earnings per share (basic and diluted) - Restated	7.05	2.00	1.65	(0.64)

32.1 Weighted average number of equity shares outstanding in all the periods also includes impact of bonus component in the rights issue. (Also refer note 3.5)  
32.2 In terms of Para 44 of AS -20, Earnings per share of current period and earlier years have been adjusted for bonus shares issued subsequent to period end. (Also refer note 3.6(b))

33 Segment reporting

The Company operates in only one segment i.e. dealing in pharma products. Accordingly there is no reportable segment in accordance with Accounting Standard 17 - Segment Reporting. Further, entire operations are located in India, hence there is no reportable geographical segment.

34 Foreign currency exposure and derivative contracts

Foreign currency exposure outstanding as at 31 December 2023: Nil (31 March 2023: Nil; 31 March 2022: Nil; 31 March 2021: Nil). There are no outstanding derivative contracts as at 31 December 2023 (31 March 2023: Nil; 31 March 2022: Nil; 31 March 2021: Nil).

35 Capital commitments, other commitments and contingent liabilities

35.1 Capital commitments

Particulars	As at 31 December 2023	As at 31 March 2023	As at 31 March 2022	As at 31 March 2021
Capital commitments (Net of capital advances)	3.75	-	-	-

35.2 Contingent liabilities (to the extent not provided for)

There are no contingent liabilities as at 31 December 2023 (31 March 2023 - Nil; 31 March 2022- Nil; 31 March 2021- Nil).



36 Financial Ratios

(a) Ratios analysis & it's elements

Financial ratios	Numerator	Denominator	For the period ended 31 December 2023	Year ended 31 March 2023	Year ended 31 March 2022	Year ended 31 March 2021
Current Ratio (times)	Current assets	Current liabilities	4.49	1.51	1.13	0.78
Debt-Equity Ratio (times)	Debt :- long term borrowings + short term borrowings	Equity: Total shareholder's funds	N.A.	0.01	0.08	(0.11)
Debt Service Coverage Ratio	Earning available for debt services :- net profit/(loss) before tax + non cash expenses tax Depreciation and Amortisation) + interest expense on borrowings	Interest + Current Maturities of long term borrowings:- interest expenses on borrowings and current maturities of long term borrowings	N.A.	N.A.	N.A.	N.A.
Return on Equity Ratio (%)	Total Profit / (loss) for the year	Total shareholder's funds	70.42%	67.67%	172.97%	91.92%
Inventory turnover ratio (times)	Cost of good sold :- Materials produced+ changes in inventories of materials in hand	Average Inventory	4.58	3.46	3.85	6.44
Trade Receivables turnover ratio (times)	Revenue from operations	Average Trade Receivables	1.93	7.16	2.61	2.04
Trade payables turnover ratio (times)	Materials produced	Average Trade Payables	0.59	0.67	0.56	0.35
Net capital turnover ratio (times)	Revenue from operations	Working Capital	2.43	7.81	42.89	(8.72)
Net profit ratio (%)	Profit / (loss) after tax	Revenue from operations	30.75%	10.32%	9.32%	-5.54%
Return on Capital employed (%)	Earning before interest & taxes (EBIT) :- profit / (loss) before tax + interest expenses	Capital Employed :- total shareholder's funds + borrowings	91.40%	83.32%	204.08%	103.05%
Return on investment (%)	Profit / (loss) after tax	Equity shareholders' fund	70.42%	67.67%	172.97%	91.92%

(b) Change in Ratios

Financial ratios	% change from 31 March 2023 to 31 December 2023*	% change from 31 March 2022 to 31 March 2023	% change from 31 March 2021 to 31 March 2022
Current Ratio (times)	NA	34%	45%
Debt-Equity Ratio (times)	NA	-91%	-173%
Debt Service Coverage Ratio	NA	NA	NA
Return on Equity Ratio (%)	NA	-61%	88%
Inventory Turnover Ratio	NA	-10%	-40%
Trade Receivables turnover ratio (time)	NA	174%	28%
Trade payables turnover ratio (times)	NA	20%	57%
Net capital turnover ratio (times)	NA	-82%	-592%
Net profit ratio (%)	NA	11%	-268%
Return on Capital employed (%)	NA	-59%	98%
Return on investment (%)	NA	-61%	88%

\* % changes in Ratio is not applicable for the period as the same is for interim period and hence not comparable





Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)  
CIN: U36994KA2017PLC105721  
Annexure V- Notes to restated financial statements  
(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

38 Additional Regulatory Information

(a) Details of Benami Property held

The Company do not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.

(b) Details of Loans and advances

There are no loans and advances granted to promoters, directors, key managerial personnel (KMPs) and the related parties which are repayable on demand or without specifying any terms or period of repayment except salary advance given to the directors and related parties in accordance with the employee advance policy of the Company.

(c) Willful Defaulter

The Company has not been declared as a willful Defaulter by any Financial Institution or bank as at the date of Balance Sheet.

(d) Relationship with Struck off Companies

The Company do not have any transactions with struck off companies.

(e) Registration of charges or satisfaction with Registrar of Companies (ROC)

The Company has no pending charges or satisfaction which are yet to be registered with the ROC beyond the Statutory period.

(f) Compliance with number of layers of companies

The Company has complied with the provision of the number of layers prescribed under clause (87) of section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017.

(g) Compliance with approved Scheme(s) of Arrangements

There are no Schemes of Arrangements has been approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013.

(h) Discrepancy in utilization of borrowings

There are no borrowings during the period except general demand loans taken from the directors in earlier years, hence the question for reporting under this clause does not arise.

(i) Utilisation of Borrowed funds and share premium:

There are no borrowings during the period except general demand loans taken from the directors in earlier years, hence the question for reporting under this clause does not arise.

(j) Undisclosed Income

The Company has no transaction that is not recorded in the books of accounts that has been surrendered or disclosed as Income during the period in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).

(k) Details of Crypto Currency or Virtual Currency

The Company has not traded or invested in Crypto currency or Virtual Currency.

39 Additional information required under Schedule III of the Companies Act, 2013 to the extent applicable has been given below.

There are no earnings and expenditure incurred in Foreign currency in the current period (31 March 2023 : Nil, 31 March 2022 : Nil, 31 March 2021 : Nil). Also, there are no remittances in foreign currency on account of dividends during the current period (31 March 2023 : Nil, 31 March 2022 : Nil, 31 March 2021 : Nil).

40 Code on Social Security, 2020

The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the Company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.

41 The Company elected to exercise the option permitted under section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019 from financial year 2021-22 onwards. Accordingly, Income Tax rate prescribed in the said section i.e. 22% as increased by applicable surcharge (10%) and cess (4%) is applicable to the Company from that financial year.


42 Change in name of the Company subsequent to period end

Pursuant to resolution passed by the Members in the Extraordinary General Meeting dated 29 December 2023 and as approved by the Registrar of the Companies subsequent to period end w.e.f. 25 January 2024, the Company has been converted from Private Limited Company into a Public Limited Company including adoption of new Memorandum of Association and new Articles of Association as applicable to the Public Company in place of existing Memorandum of Association and Articles of Association of the Company.

43 The Previous year's figures have been regrouped /reclassified, wherever considered necessary.

As per our report of even date

For SKLR & Co. LLP  
Chartered Accountants  
Firm Registration No. W100362

  
Lateesh Gada  
Partner  
Membership No. 155995  
UDIN No. 24155999BKAJAC6306

Place: Bangalore  
Date: 13-04-2024



For and on behalf of the Board of Directors of  
Amwill Health Care Limited (Formerly known as Amwill  
Health Care Private Limited)

  
Tarun Gandhi  
Managing Director  
DIN: 07854698  
  
Sharanya Nagaraj  
Chief financial officer

Place: Bangalore  
Date: 13-04-2024

  
Anand Gandhi  
Managing Director  
DIN: 07854706  
  
Sapna Barpar  
Company Secretary

